Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Chemical metabolic inhibitors for the treatment of blood-borne cancers.

Villalba M, Lopez-Royuela N, Krzywinska E, Rathore MG, Hipskind RA, Haouas H, Allende-Vega N.

Anticancer Agents Med Chem. 2014 Feb;14(2):223-32. Review.

2.

Dimer formation and conformational flexibility ensure cytoplasmic stability and nuclear accumulation of Elk-1.

Evans EL, Saxton J, Shelton SJ, Begitt A, Holliday ND, Hipskind RA, Shaw PE.

Nucleic Acids Res. 2011 Aug;39(15):6390-402. doi: 10.1093/nar/gkr266. Epub 2011 May 4.

3.

Oxidative phosphorylation induces de novo expression of the MHC class I in tumor cells through the ERK5 pathway.

Charni S, de Bettignies G, Rathore MG, Aguiló JI, van den Elsen PJ, Haouzi D, Hipskind RA, Enriquez JA, Sanchez-Beato M, Pardo J, Anel A, Villalba M.

J Immunol. 2010 Sep 15;185(6):3498-503. doi: 10.4049/jimmunol.1001250. Epub 2010 Aug 20.

4.

Basic fibroblast growth factor induces matrix metalloproteinase-13 via ERK MAP kinase-altered phosphorylation and sumoylation of Elk-1 in human adult articular chondrocytes.

Im HJ, Sharrocks AD, Lin X, Yan D, Kim J, van Wijnen AJ, Hipskind RA.

Open Access Rheumatol. 2009 Oct 31;1:151-161. eCollection 2009.

5.

ERK5 knockdown generates mouse leukemia cells with low MHC class I levels that activate NK cells and block tumorigenesis.

Charni S, Aguilo JI, Garaude J, de Bettignies G, Jacquet C, Hipskind RA, Singer D, Anel A, Villalba M.

J Immunol. 2009 Mar 15;182(6):3398-405. doi: 10.4049/jimmunol.0803006.

6.

TC10 controls human myofibril organization and is activated by the sarcomeric RhoGEF obscurin.

Coisy-Quivy M, Touzet O, Bourret A, Hipskind RA, Mercier J, Fort P, Philips A.

J Cell Sci. 2009 Apr 1;122(Pt 7):947-56. doi: 10.1242/jcs.040121. Epub 2009 Mar 3.

7.

Erk5 controls Slug expression and keratinocyte activation during wound healing.

Arnoux V, Nassour M, L'Helgoualc'h A, Hipskind RA, Savagner P.

Mol Biol Cell. 2008 Nov;19(11):4738-49. doi: 10.1091/mbc.E07-10-1078. Epub 2008 Aug 20.

8.

Impaired anti-leukemic immune response in PKCtheta-deficient mice.

Garaude J, Kaminski S, Charni S, Aguilò JI, Jacquet C, Plays M, Hernandez J, Rodriguez F, Hipskind RA, Anel A, Villalba M.

Mol Immunol. 2008 Jul;45(12):3463-9. doi: 10.1016/j.molimm.2008.03.016. Epub 2008 May 6.

PMID:
18462800
9.

SUMOylation regulates the transcriptional activity of JunB in T lymphocytes.

Garaude J, Farrás R, Bossis G, Charni S, Piechaczyk M, Hipskind RA, Villalba M.

J Immunol. 2008 May 1;180(9):5983-90.

10.

ERK5 activates NF-kappaB in leukemic T cells and is essential for their growth in vivo.

Garaude J, Cherni S, Kaminski S, Delepine E, Chable-Bessia C, Benkirane M, Borges J, Pandiella A, Iñiguez MA, Fresno M, Hipskind RA, Villalba M.

J Immunol. 2006 Dec 1;177(11):7607-17.

11.

Cell type-dependent control of NF-Y activity by TGF-beta.

Alabert C, Rogers L, Kahn L, Niellez S, Fafet P, Cerulis S, Blanchard JM, Hipskind RA, Vignais ML.

Oncogene. 2006 Jun 8;25(24):3387-96. Epub 2006 Jan 23.

PMID:
16434965
12.

The role of ERK5 in T-cell signalling.

Garaude J, Kaminski S, Cherni S, Hipskind RA, Villalba M.

Scand J Immunol. 2005 Dec;62(6):515-20.

13.

[SUMO pins Elk-1 in the nucleus].

Salinas S, Hipskind RA.

Med Sci (Paris). 2005 Feb;21(2):121-3. French. No abstract available.

14.

Positive feedback regulation of PLCgamma1/Ca(2+) signaling by PKCtheta in restimulated T cells via a Tec kinase-dependent pathway.

Altman A, Kaminski S, Busuttil V, Droin N, Hu J, Tadevosyan Y, Hipskind RA, Villalba M.

Eur J Immunol. 2004 Jul;34(7):2001-11.

15.

SUMOylation regulates nucleo-cytoplasmic shuttling of Elk-1.

Salinas S, Briançon-Marjollet A, Bossis G, Lopez MA, Piechaczyk M, Jariel-Encontre I, Debant A, Hipskind RA.

J Cell Biol. 2004 Jun 21;165(6):767-73.

16.

Distinct functions of Vav1 in JNK1 activation in Jurkat T cells versus non-haematopoietic cells.

Kaminski S, Del Pozo MA, Hipskind RA, Altman A, Villalba M.

Scand J Immunol. 2004 Jun;59(6):527-35.

17.

Multinucleated osteoclast formation in vivo and in vitro by P2X7 receptor-deficient mice.

Gartland A, Buckley KA, Hipskind RA, Perry MJ, Tobias JH, Buell G, Chessell I, Bowler WB, Gallagher JA.

Crit Rev Eukaryot Gene Expr. 2003;13(2-4):243-53.

PMID:
14696971
18.

P2 receptors in bone--modulation of osteoclast formation and activity via P2X7 activation.

Gartland A, Buckley KA, Hipskind RA, Bowler WB, Gallagher JA.

Crit Rev Eukaryot Gene Expr. 2003;13(2-4):237-42. Review.

PMID:
14696970
19.

Activation of cyclin D1 expression by the ERK5 cascade.

Mulloy R, Salinas S, Philips A, Hipskind RA.

Oncogene. 2003 Aug 21;22(35):5387-98.

PMID:
12934098
20.

Immediate-early gene induction by the stresses anisomycin and arsenite in human osteosarcoma cells involves MAPK cascade signaling to Elk-1, CREB and SRF.

Bébien M, Salinas S, Becamel C, Richard V, Linares L, Hipskind RA.

Oncogene. 2003 Mar 27;22(12):1836-47.

PMID:
12660819
21.
22.

Oct-1 potentiates CREB-driven cyclin D1 promoter activation via a phospho-CREB- and CREB binding protein-independent mechanism.

Boulon S, Dantonel JC, Binet V, Vié A, Blanchard JM, Hipskind RA, Philips A.

Mol Cell Biol. 2002 Nov;22(22):7769-79.

23.

Dopamine induces a PI3-kinase-independent activation of Akt in striatal neurons: a new route to cAMP response element-binding protein phosphorylation.

Brami-Cherrier K, Valjent E, Garcia M, Pagès C, Hipskind RA, Caboche J.

J Neurosci. 2002 Oct 15;22(20):8911-21.

24.

Activation of metabotropic glutamate receptor subtype 1/protein kinase C/mitogen-activated protein kinase pathway is required for postischemic long-term potentiation in the striatum.

Calabresi P, Saulle E, Marfia GA, Centonze D, Mulloy R, Picconi B, Hipskind RA, Conquet F, Bernardi G.

Mol Pharmacol. 2001 Oct;60(4):808-15.

PMID:
11562444
25.

Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine.

Calabresi P, Gubellini P, Picconi B, Centonze D, Pisani A, Bonsi P, Greengard P, Hipskind RA, Borrelli E, Bernardi G.

J Neurosci. 2001 Jul 15;21(14):5110-20.

26.

Extracellular nucleotide signaling: a mechanism for integrating local and systemic responses in the activation of bone remodeling.

Bowler WB, Buckley KA, Gartland A, Hipskind RA, Bilbe G, Gallagher JA.

Bone. 2001 May;28(5):507-12. Review.

PMID:
11344050
27.

Expression of a P2X7 receptor by a subpopulation of human osteoblasts.

Gartland A, Hipskind RA, Gallagher JA, Bowler WB.

J Bone Miner Res. 2001 May;16(5):846-56.

28.
29.

Parathyroid hormone potentiates nucleotide-induced [Ca2+]i release in rat osteoblasts independently of Gq activation or cyclic monophosphate accumulation. A mechanism for localizing systemic responses in bone.

Buckley KA, Wagstaff SC, McKay G, Gaw A, Hipskind RA, Bilbe G, Gallagher JA, Bowler WB.

J Biol Chem. 2001 Mar 23;276(12):9565-71. Epub 2000 Dec 21.

30.
31.

Opposing roles of Elk-1 and its brain-specific isoform, short Elk-1, in nerve growth factor-induced PC12 differentiation.

Vanhoutte P, Nissen JL, Brugg B, Gaspera BD, Besson MJ, Hipskind RA, Caboche J.

J Biol Chem. 2001 Feb 16;276(7):5189-96. Epub 2000 Oct 24.

32.
33.

A novel calcium signaling pathway targets the c-fos intragenic transcriptional pausing site.

Coulon V, Veyrune JL, Tourkine N, Vié A, Hipskind RA, Blanchard JM.

J Biol Chem. 1999 Oct 22;274(43):30439-46.

35.

Glutamate induces phosphorylation of Elk-1 and CREB, along with c-fos activation, via an extracellular signal-regulated kinase-dependent pathway in brain slices.

Vanhoutte P, Barnier JV, Guibert B, Pagès C, Besson MJ, Hipskind RA, Caboche J.

Mol Cell Biol. 1999 Jan;19(1):136-46.

36.

MAP kinase signaling cascades and gene expression in osteoblasts.

Hipskind RA, Bilbe G.

Front Biosci. 1998 Aug 1;3:d804-16. Review.

PMID:
9682034
37.
38.
39.

Interphase cytogenetic analysis of distinct X-chromosomal translocation breakpoints in synovial sarcoma.

Janz M, De Leeuw B, Weghuis DO, Werner M, Nolte M, Geurts Van Kessel A, Nordheim A, Hipskind RA.

J Pathol. 1995 Apr;175(4):391-6.

PMID:
7790992
40.

Ras-dependent and -independent pathways target the mitogen-activated protein kinase network in macrophages.

Büscher D, Hipskind RA, Krautwald S, Reimann T, Baccarini M.

Mol Cell Biol. 1995 Jan;15(1):466-75.

41.

Lipopolysaccharide induces activation of the Raf-1/MAP kinase pathway. A putative role for Raf-1 in the induction of the IL-1 beta and the TNF-alpha genes.

Reimann T, Büscher D, Hipskind RA, Krautwald S, Lohmann-Matthes ML, Baccarini M.

J Immunol. 1994 Dec 15;153(12):5740-9.

PMID:
7989771
42.

Refined mapping of the human Ets-related gene Elk-1 to Xp11.2-p11.4, distal to the OATL1 region.

Janz M, Lehmann U, Olde Weghuis D, de Leeuw B, Geurts van Kessel A, Gilgenkrantz S, Hipskind RA, Nordheim A.

Hum Genet. 1994 Oct;94(4):442-4.

PMID:
7927346
43.

Heterogeneity of ternary complex factors in HeLa cell nuclear extracts.

Pingoud V, Zinck R, Hipskind RA, Janknecht R, Nordheim A.

J Biol Chem. 1994 Sep 16;269(37):23310-7.

45.

Ras/MAP kinase-dependent and -independent signaling pathways target distinct ternary complex factors.

Hipskind RA, Büscher D, Nordheim A, Baccarini M.

Genes Dev. 1994 Aug 1;8(15):1803-16.

46.

A factor induced by differentiation signals in cells of the macrophage lineage binds to the gamma interferon activation site.

Eilers A, Baccarini M, Horn F, Hipskind RA, Schindler C, Decker T.

Mol Cell Biol. 1994 Feb;14(2):1364-73.

47.

v-raf confers CSF-1 independent growth to a macrophage cell line and leads to immediate early gene expression without MAP-kinase activation.

Büscher D, Dello Sbarba P, Hipskind RA, Rapp UR, Stanley ER, Baccarini M.

Oncogene. 1993 Dec;8(12):3323-32.

PMID:
8247534
48.
49.

Analysis of transcriptional stimulation by recombinant Oct proteins in a cell-free system.

Annweiler A, Zwilling S, Hipskind RA, Wirth T.

J Biol Chem. 1993 Feb 5;268(4):2525-34.

50.

Identification of multiple SRF N-terminal phosphorylation sites affecting DNA binding properties.

Janknecht R, Hipskind RA, Houthaeve T, Nordheim A, Stunnenberg HG.

EMBO J. 1992 Mar;11(3):1045-54.

Supplemental Content

Loading ...
Support Center